Befriend the Trend Trading Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Befriend the Trend Trading

SPY 681.44

+1.6%

Nov 10 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Dr. Stoxx	10/12/2007 10:26:14 AM
	of 39683

TEVA (another longer term hold for us in one of our NL's) out with news this morning: 10:19 TEVA Teva Pharm: Long-Term study shows COPAXONE significantly slows progression of disability; reduces rates in patients with relapsing-remitting Multiple Sclerosis (45.06 +0.19) -Update- Co notes data from a 16-year follow-up study of 174 relapsing-remitting multiple sclerosis patients was presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. The study demonstrates significant clinical benefits on both disability and relapse rates in patients continuously treated with COPAXONE for an average of 8 years. The majority of patients in the ongoing cohort, who continuously received COPAXONE showed either unchanged or improved disability scores, as measured by Expanded Disability Status Scale. In contrast, more than half of patients who discontinued treatment after an average of 3.7 years showed accumulated disability. In addition, 76 percent of patients who remained on COPAXONE were still walking unaided after an average of 20 years of disease duration.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next